BR112021025810A2 - Compostos radiomarcados direcionando o antígeno de membrana específico da próstata - Google Patents
Compostos radiomarcados direcionando o antígeno de membrana específico da próstataInfo
- Publication number
- BR112021025810A2 BR112021025810A2 BR112021025810A BR112021025810A BR112021025810A2 BR 112021025810 A2 BR112021025810 A2 BR 112021025810A2 BR 112021025810 A BR112021025810 A BR 112021025810A BR 112021025810 A BR112021025810 A BR 112021025810A BR 112021025810 A2 BR112021025810 A2 BR 112021025810A2
- Authority
- BR
- Brazil
- Prior art keywords
- specific membrane
- membrane antigen
- radiolabeled compounds
- prostate
- compounds targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865088P | 2019-06-21 | 2019-06-21 | |
| US202063006643P | 2020-04-07 | 2020-04-07 | |
| PCT/CA2020/050864 WO2020252598A1 (en) | 2019-06-21 | 2020-06-19 | Radiolabeled compounds targeting the prostate-specific membrane antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025810A2 true BR112021025810A2 (pt) | 2022-05-10 |
Family
ID=74036930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025810A BR112021025810A2 (pt) | 2019-06-21 | 2020-06-19 | Compostos radiomarcados direcionando o antígeno de membrana específico da próstata |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11504441B2 (https=) |
| EP (1) | EP3986872A4 (https=) |
| JP (2) | JP7618599B2 (https=) |
| KR (1) | KR20220024595A (https=) |
| CN (2) | CN114401947B (https=) |
| AU (1) | AU2020296488A1 (https=) |
| BR (1) | BR112021025810A2 (https=) |
| CA (1) | CA3144094A1 (https=) |
| IL (1) | IL288960B1 (https=) |
| WO (1) | WO2020252598A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210909A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| GB202005282D0 (en) | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| WO2022178592A1 (en) * | 2021-02-26 | 2022-09-01 | Telix International Pty Ltd | Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents |
| CN115806529A (zh) * | 2021-09-15 | 2023-03-17 | 威智医药有限公司 | Psma结合剂及其用途 |
| JP2024544870A (ja) * | 2021-11-10 | 2024-12-05 | スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド | Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 |
| CA3244865A1 (en) * | 2022-03-04 | 2023-09-07 | Provincial Health Services Authority | RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| WO2024016071A1 (en) * | 2022-07-18 | 2024-01-25 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN118344391A (zh) * | 2023-01-13 | 2024-07-16 | 浙江普利药业有限公司 | 一种新的用于硼中子捕获疗法的含硼化合物 |
| EP4667019A1 (en) * | 2023-02-16 | 2025-12-24 | Norroy Bioscience Co., Ltd. | Psma-targeted radiopharmaceutical, and synthesis and use thereof |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| CN116730983B (zh) * | 2023-08-10 | 2023-11-03 | 山东大学 | 一种靶向前列腺特异性抗原的化合物及其制备方法与应用 |
| CN121773094A (zh) | 2023-09-12 | 2026-03-31 | 上海先通生物科技有限公司 | 前列腺特异性膜抗原的抑制剂和其用途 |
| WO2025055943A1 (en) | 2023-09-12 | 2025-03-20 | Shanghai Sinotau Biotech. Co., Ltd | Inhibitors of prostate specific membrane antigen and use thereof |
| CN117045828A (zh) * | 2023-10-12 | 2023-11-14 | 北京先通国际医药科技股份有限公司 | 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途 |
| CN119101006B (zh) * | 2024-09-05 | 2025-11-07 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性标记物及制法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650134A (en) | 1993-01-12 | 1997-07-22 | Novartis Ag (Formerly Sandoz Ltd.) | Peptides |
| US7563433B2 (en) | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| CA2555597C (en) | 2004-02-13 | 2016-06-14 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
| US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| ES2847275T3 (es) | 2006-11-08 | 2021-08-02 | Molecular Insight Pharm Inc | Heterodímeros de ácido glutámico |
| CA2926573C (en) | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| CA2731645C (en) | 2007-07-24 | 2017-05-23 | The University Of British Columbia | Substituted aryl-fluoroborates as imaging agents |
| RU2494096C2 (ru) | 2008-08-01 | 2013-09-27 | Дзе Джонс Хопкинс Юниверсити | Агенты, связывающиеся с psma, и их применение |
| WO2012094334A1 (en) | 2011-01-04 | 2012-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates |
| CN103687627A (zh) | 2011-03-01 | 2014-03-26 | 通用电气健康护理有限公司 | 作为pet示踪剂的放射性标记的奥曲肽酸类似物 |
| WO2013028664A1 (en) | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
| WO2013028791A1 (en) | 2011-08-22 | 2013-02-28 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
| BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| US20140147381A1 (en) | 2012-11-29 | 2014-05-29 | Gregory David Espenan | 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment |
| CA2903281C (en) | 2013-03-08 | 2022-11-29 | The University Of British Columbia | Substituted organofluoroborates as imaging agents |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| WO2015100498A1 (en) | 2014-01-03 | 2015-07-09 | British Columbia Cancer Agency Branch | Compositions and methods for imaging cancer |
| WO2015135082A1 (en) | 2014-03-13 | 2015-09-17 | British Columbia Cancer Agency Branch | Bradykinin receptor b1 targeting probes |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| EP3544960A1 (en) | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
| CN106967152B (zh) | 2017-03-28 | 2019-11-26 | 江苏省原子医学研究所 | 一种氟-18标记的化合物及其制备方法与应用 |
| US11629201B2 (en) | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| CN115322244B (zh) * | 2017-06-06 | 2025-10-28 | 透明医药有限公司 | 放射性药物、放射成像剂及其用途 |
| US20200339625A1 (en) | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| BR112020011727A2 (pt) | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| WO2020065045A1 (en) | 2018-09-28 | 2020-04-02 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| AU2019407851B8 (en) | 2018-12-18 | 2025-10-09 | Provincial Health Services Authority | Dual mode 18f-labelled theranostic compounds and uses thereof |
-
2020
- 2020-06-19 CN CN202080050494.8A patent/CN114401947B/zh active Active
- 2020-06-19 KR KR1020227001449A patent/KR20220024595A/ko active Pending
- 2020-06-19 JP JP2021576163A patent/JP7618599B2/ja active Active
- 2020-06-19 EP EP20825937.4A patent/EP3986872A4/en active Pending
- 2020-06-19 CN CN202411581546.0A patent/CN119431260A/zh active Pending
- 2020-06-19 WO PCT/CA2020/050864 patent/WO2020252598A1/en not_active Ceased
- 2020-06-19 BR BR112021025810A patent/BR112021025810A2/pt unknown
- 2020-06-19 AU AU2020296488A patent/AU2020296488A1/en active Pending
- 2020-06-19 CA CA3144094A patent/CA3144094A1/en active Pending
-
2021
- 2021-07-09 US US17/371,587 patent/US11504441B2/en active Active
- 2021-12-13 IL IL288960A patent/IL288960B1/en unknown
-
2022
- 2022-10-06 US US17/961,299 patent/US20230114807A1/en active Pending
-
2025
- 2025-01-08 JP JP2025002658A patent/JP2025069156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022537773A (ja) | 2022-08-29 |
| CN114401947B (zh) | 2024-11-29 |
| EP3986872A1 (en) | 2022-04-27 |
| CA3144094A1 (en) | 2020-12-24 |
| AU2020296488A1 (en) | 2022-01-20 |
| CN119431260A (zh) | 2025-02-14 |
| CN114401947A (zh) | 2022-04-26 |
| US20230114807A1 (en) | 2023-04-13 |
| IL288960A (en) | 2022-02-01 |
| KR20220024595A (ko) | 2022-03-03 |
| JP2025069156A (ja) | 2025-04-30 |
| WO2020252598A1 (en) | 2020-12-24 |
| US20210338851A1 (en) | 2021-11-04 |
| EP3986872A4 (en) | 2024-02-21 |
| US11504441B2 (en) | 2022-11-22 |
| IL288960B1 (en) | 2026-03-01 |
| JP7618599B2 (ja) | 2025-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021025810A2 (pt) | Compostos radiomarcados direcionando o antígeno de membrana específico da próstata | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| BR112023000770A2 (pt) | Inibidor de egfr | |
| BR112016028345A2 (pt) | composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto. | |
| BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
| BR112017018872A2 (pt) | combinação de um antagonista pd-1 e eribulina para tratamento de câncer | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| BR112018073642A2 (pt) | imunomoduladores para imagiologia tep | |
| BR112015013611A2 (pt) | composto, e, composição farmacêutica | |
| BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
| BRPI0821855B8 (pt) | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| EP3695839A4 (en) | THERAPEUTIC AGENT WITH AXL INHIBITOR AS AN ACTIVE INGREDIENT FOR SOLID TUMORS | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| BRPI0706992C8 (pt) | composto de fórmula (i) e formulação farmacêutica | |
| BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
| AR101177A1 (es) | Inhibidores de la syk | |
| BR112018074632A2 (pt) | combinações compreendendo inibidores de histona desacetilase | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| EA201890221A1 (ru) | Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов | |
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| BR112015022385A2 (pt) | droga para uma doença respiratória | |
| BR112019007145A2 (pt) | combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025011654-8 PROTOCOLO 870250047911 EM 09/06/2025 14:09. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |